Reji Biology's (688068.SH) subsidiary's clinical trial application for the innovative drug SGT003 injection has been approved.

Zhijun Finance and Economics APP News, Rejing Bio (688068.SH) announced recently that its subsidiary Beijing Shunjing Biomedical Technology Co., Ltd. (referred to as "Shunjing Medicine") has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA). The application for clinical trials of the innovative drug SGT003 injection developed by Shunjing Medicine has been approved by the NMPA.